Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 244 entries
Sorted by: Best Match Show Resources per page
Accelerated idioventricular rhythm observed under total intravenous anesthesia using remifentanil, propofol, and rocuronium.

JA clinical reports

Nakanishi M, Masumo K, Oota T, Kato T, Imanishi T.
PMID: 29497644
JA Clin Rep. 2015;1(1):12. doi: 10.1186/s40981-015-0016-3. Epub 2015 Sep 07.

Accelerated idioventricular rhythm (AIVR) during anesthesia has been described in several drug toxicity such as from cocaine, halothane, desflurane, and propofol. We present the case of a man who developed episodes of AIVR observed under total intravenous anesthesia (TIVA)...

Cite
Nakanishi M, Masumo K, Oota T, et al. Accelerated idioventricular rhythm observed under total intravenous anesthesia using remifentanil, propofol, and rocuronium. JA Clin Rep. 2015;1(1):12doi: 10.1186/s40981-015-0016-3.
Nakanishi, M., Masumo, K., Oota, T., Kato, T., & Imanishi, T. (2015). Accelerated idioventricular rhythm observed under total intravenous anesthesia using remifentanil, propofol, and rocuronium. JA clinical reports, 1(1), 12. https://doi.org/10.1186/s40981-015-0016-3
Nakanishi, Mika, et al. "Accelerated idioventricular rhythm observed under total intravenous anesthesia using remifentanil, propofol, and rocuronium." JA clinical reports vol. 1,1 (2015): 12. doi: https://doi.org/10.1186/s40981-015-0016-3
Nakanishi M, Masumo K, Oota T, Kato T, Imanishi T. Accelerated idioventricular rhythm observed under total intravenous anesthesia using remifentanil, propofol, and rocuronium. JA Clin Rep. 2015;1(1):12. doi: 10.1186/s40981-015-0016-3. Epub 2015 Sep 07. PMID: 29497644; PMCID: PMC5818701.
Copy Download .nbib Format: NLM
Mutations in KATNB1 Cause Complex Cerebral Malformations by Disrupting Asymmetrically Dividing Neural Progenitors.

Neuron

Mishra-Gorur K, Çağlayan AO, Schaffer AE, Chabu C, Henegariu O, Vonhoff F, Akgümüş GT, Nishimura S, Han W, Tu S, Baran B, Gümüş H, Dilber C, Zaki MS, Hossni HAA, Rivière JB, Kayserili H, Spencer EG, Rosti RÖ, Schroth J, Per H, Çağlar C, Çağlar Ç, Dölen D, Baranoski JF, Kumandaş S, Minja FJ, Erson-Omay EZ, Mane SM, Lifton RP, Xu T, Keshishian H, Dobyns WB, Chi NC, Šestan N, Louvi A, Bilgüvar K, Yasuno K, Gleeson JG, Günel M.
PMID: 29654772
Neuron. 2015 Jan 07;85(1):228. doi: 10.1016/j.neuron.2014.12.046. Epub 2015 Jan 07.

No abstract available.

Cite
Mishra-Gorur K, Çağlayan AO, Schaffer AE, et al. Mutations in KATNB1 Cause Complex Cerebral Malformations by Disrupting Asymmetrically Dividing Neural Progenitors. Neuron. 2015;85(1):228doi: 10.1016/j.neuron.2014.12.046.
Mishra-Gorur, K., Çağlayan, A. O., Schaffer, A. E., Chabu, C., Henegariu, O., Vonhoff, F., Akgümüş, G. T., Nishimura, S., Han, W., Tu, S., Baran, B., Gümüş, H., Dilber, C., Zaki, M. S., Hossni, H. A. A., Rivière, J. B., Kayserili, H., Spencer, E. G., Rosti, R. �. �., Schroth, J., Per, H., Çağlar, C., Çağlar, �. �., Dölen, D., Baranoski, J. F., Kumandaş, S., Minja, F. J., Erson-Omay, E. Z., Mane, S. M., Lifton, R. P., Xu, T., Keshishian, H., Dobyns, W. B., Chi, N. C., Šestan, N., Louvi, A., Bilgüvar, K., Yasuno, K., Gleeson, J. G., & Günel, M. (2015). Mutations in KATNB1 Cause Complex Cerebral Malformations by Disrupting Asymmetrically Dividing Neural Progenitors. Neuron, 85(1), 228. https://doi.org/10.1016/j.neuron.2014.12.046
Mishra-Gorur, Ketu, et al. "Mutations in KATNB1 Cause Complex Cerebral Malformations by Disrupting Asymmetrically Dividing Neural Progenitors." Neuron vol. 85,1 (2015): 228. doi: https://doi.org/10.1016/j.neuron.2014.12.046
Mishra-Gorur K, Çağlayan AO, Schaffer AE, Chabu C, Henegariu O, Vonhoff F, Akgümüş GT, Nishimura S, Han W, Tu S, Baran B, Gümüş H, Dilber C, Zaki MS, Hossni HAA, Rivière JB, Kayserili H, Spencer EG, Rosti RÖ, Schroth J, Per H, Çağlar C, Çağlar Ç, Dölen D, Baranoski JF, Kumandaş S, Minja FJ, Erson-Omay EZ, Mane SM, Lifton RP, Xu T, Keshishian H, Dobyns WB, Chi NC, Šestan N, Louvi A, Bilgüvar K, Yasuno K, Gleeson JG, Günel M. Mutations in KATNB1 Cause Complex Cerebral Malformations by Disrupting Asymmetrically Dividing Neural Progenitors. Neuron. 2015 Jan 07;85(1):228. doi: 10.1016/j.neuron.2014.12.046. Epub 2015 Jan 07. PMID: 29654772.
Copy Download .nbib Format: NLM
Association of .

Clinical cancer research : an official journal of the American Association for Cancer Research

Borowsky J, Haruki K, Lau MC, Dias Costa A, Väyrynen JP, Ugai T, Arima K, da Silva A, Felt KD, Zhao M, Gurjao C, Twombly TS, Fujiyoshi K, Väyrynen SA, Hamada T, Mima K, Bullman S, Harrison TA, Phipps AI, Peters U, Ng K, Meyerhardt JA, Song M, Giovannucci EL, Wu K, Zhang X, Freeman GJ, Huttenhower C, Garrett WS, Chan AT, Leggett BA, Whitehall VLJ, Walker N, Brown I, Bettington M, Nishihara R, Fuchs CS, Lennerz JK, Giannakis M, Nowak JA, Ogino S.
PMID: 33632927
Clin Cancer Res. 2021 May 15;27(10):2816-2826. doi: 10.1158/1078-0432.CCR-20-4009. Epub 2021 Feb 25.

PURPOSE: While evidence indicates that EXPERIMENTAL DESIGN: We measured RESULTS: The amount of CONCLUSIONS: The amount of tissue

Cite
Borowsky J, Haruki K, Lau MC, et al. Association of . Clin Cancer Res. 2021;27(10):2816-2826doi: 10.1158/1078-0432.CCR-20-4009.
Borowsky, J., Haruki, K., Lau, M. C., Dias Costa, A., Väyrynen, J. P., Ugai, T., Arima, K., da Silva, A., Felt, K. D., Zhao, M., Gurjao, C., Twombly, T. S., Fujiyoshi, K., Väyrynen, S. A., Hamada, T., Mima, K., Bullman, S., Harrison, T. A., Phipps, A. I., Peters, U., Ng, K., Meyerhardt, J. A., Song, M., Giovannucci, E. L., Wu, K., Zhang, X., Freeman, G. J., Huttenhower, C., Garrett, W. S., Chan, A. T., Leggett, B. A., Whitehall, V. L. J., Walker, N., Brown, I., Bettington, M., Nishihara, R., Fuchs, C. S., Lennerz, J. K., Giannakis, M., Nowak, J. A., & Ogino, S. (2021). Association of . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2816-2826. https://doi.org/10.1158/1078-0432.CCR-20-4009
Borowsky, Jennifer, et al. "Association of ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2816-2826. doi: https://doi.org/10.1158/1078-0432.CCR-20-4009
Borowsky J, Haruki K, Lau MC, Dias Costa A, Väyrynen JP, Ugai T, Arima K, da Silva A, Felt KD, Zhao M, Gurjao C, Twombly TS, Fujiyoshi K, Väyrynen SA, Hamada T, Mima K, Bullman S, Harrison TA, Phipps AI, Peters U, Ng K, Meyerhardt JA, Song M, Giovannucci EL, Wu K, Zhang X, Freeman GJ, Huttenhower C, Garrett WS, Chan AT, Leggett BA, Whitehall VLJ, Walker N, Brown I, Bettington M, Nishihara R, Fuchs CS, Lennerz JK, Giannakis M, Nowak JA, Ogino S. Association of . Clin Cancer Res. 2021 May 15;27(10):2816-2826. doi: 10.1158/1078-0432.CCR-20-4009. Epub 2021 Feb 25. PMID: 33632927; PMCID: PMC8127352.
Copy Download .nbib Format: NLM
A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer.

JNCI cancer spectrum

Zhang C, Mei Z, Pei J, Abe M, Zeng X, Huang Q, Nishiyama K, Akimoto N, Haruki K, Nan H, Meyerhardt JA, Zhang R, Li X, Ogino S, Ugai T.
PMID: 33554032
JNCI Cancer Spectr. 2020 Oct 16;5(1):pkaa093. doi: 10.1093/jncics/pkaa093. eCollection 2021 Feb.

BACKGROUND: The American Joint Committee on Cancer (AJCC) 8th tumor-node-metastasis (TNM) classification for colorectal cancer (CRC) has limited ability to predict prognosis.METHODS: We included 45 379 eligible stage I-III CRC patients from the Surveillance, Epidemiology, and End Results Program....

Cite
Zhang C, Mei Z, Pei J, et al. A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer. JNCI Cancer Spectr. 2020;5(1):pkaa093doi: 10.1093/jncics/pkaa093.
Zhang, C., Mei, Z., Pei, J., Abe, M., Zeng, X., Huang, Q., Nishiyama, K., Akimoto, N., Haruki, K., Nan, H., Meyerhardt, J. A., Zhang, R., Li, X., Ogino, S., & Ugai, T. (2021). A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer. JNCI cancer spectrum, 5(1), pkaa093. https://doi.org/10.1093/jncics/pkaa093
Zhang, Chundong, et al. "A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer." JNCI cancer spectrum vol. 5,1 (2021): pkaa093. doi: https://doi.org/10.1093/jncics/pkaa093
Zhang C, Mei Z, Pei J, Abe M, Zeng X, Huang Q, Nishiyama K, Akimoto N, Haruki K, Nan H, Meyerhardt JA, Zhang R, Li X, Ogino S, Ugai T. A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer. JNCI Cancer Spectr. 2020 Oct 16;5(1):pkaa093. doi: 10.1093/jncics/pkaa093. eCollection 2021 Feb. PMID: 33554032; PMCID: PMC7853182.
Copy Download .nbib Format: NLM
Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors.

Oncology letters

Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Sakai R, Nakayama H, Hatori S, Toda S, Masudo K.
PMID: 31186746
Oncol Lett. 2019 Jun;17(6):5292-5300. doi: 10.3892/ol.2019.10180. Epub 2019 Mar 21.

In patients with distant metastasis, treatment for differentiated thyroid cancer (DTC) includes complete total thyroidectomy, followed by radioactive iodine (RAI) therapy for metastatic lesions. Tyrosine kinase inhibitor (TKI) treatment is the final treatment option for metastatic lesions, which is...

Cite
Iwasaki H, Yamazaki H, Takasaki H, et al. Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. Oncol Lett. 2019;17(6):5292-5300doi: 10.3892/ol.2019.10180.
Iwasaki, H., Yamazaki, H., Takasaki, H., Suganuma, N., Sakai, R., Nakayama, H., Hatori, S., Toda, S., & Masudo, K. (2019). Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. Oncology letters, 17(6), 5292-5300. https://doi.org/10.3892/ol.2019.10180
Iwasaki, Hiroyuki, et al. "Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors." Oncology letters vol. 17,6 (2019): 5292-5300. doi: https://doi.org/10.3892/ol.2019.10180
Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Sakai R, Nakayama H, Hatori S, Toda S, Masudo K. Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. Oncol Lett. 2019 Jun;17(6):5292-5300. doi: 10.3892/ol.2019.10180. Epub 2019 Mar 21. PMID: 31186746; PMCID: PMC6507323.
Copy Download .nbib Format: NLM
Pleural Effusion Caused by .

Frontiers in medicine

Niitsu T, Kuge T, Fukushima K, Matsumoto Y, Abe Y, Okamoto M, Haduki K, Saito H, Nitta T, Kawano A, Matsuki T, Motooka D, Tsujino K, Miki K, Nakamura S, Kida H, Kumanogoh A.
PMID: 34901097
Front Med (Lausanne). 2021 Nov 24;8:797171. doi: 10.3389/fmed.2021.797171. eCollection 2021.

No abstract available.

Cite
Niitsu T, Kuge T, Fukushima K, et al. Pleural Effusion Caused by . Front Med (Lausanne). 2021;8:797171doi: 10.3389/fmed.2021.797171.
Niitsu, T., Kuge, T., Fukushima, K., Matsumoto, Y., Abe, Y., Okamoto, M., Haduki, K., Saito, H., Nitta, T., Kawano, A., Matsuki, T., Motooka, D., Tsujino, K., Miki, K., Nakamura, S., Kida, H., & Kumanogoh, A. (2021). Pleural Effusion Caused by . Frontiers in medicine, 8797171. https://doi.org/10.3389/fmed.2021.797171
Niitsu, Takayuki, et al. "Pleural Effusion Caused by ." Frontiers in medicine vol. 8 (2021): 797171. doi: https://doi.org/10.3389/fmed.2021.797171
Niitsu T, Kuge T, Fukushima K, Matsumoto Y, Abe Y, Okamoto M, Haduki K, Saito H, Nitta T, Kawano A, Matsuki T, Motooka D, Tsujino K, Miki K, Nakamura S, Kida H, Kumanogoh A. Pleural Effusion Caused by . Front Med (Lausanne). 2021 Nov 24;8:797171. doi: 10.3389/fmed.2021.797171. eCollection 2021. PMID: 34901097; PMCID: PMC8651622.
Copy Download .nbib Format: NLM
Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review.

Cardio-oncology (London, England)

Kazama S, Morimoto R, Kimura Y, Shibata N, Ozaki R, Araki T, Mizutani T, Oishi H, Arao Y, Kuwayama T, Hiraiwa H, Kondo T, Furusawa K, Shimokata T, Okumura T, Bando YK, Ando Y, Murohara T.
PMID: 34229760
Cardiooncology. 2021 Jul 06;7(1):26. doi: 10.1186/s40959-021-00112-z.

BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in cancer treatment as the use of these drugs has become more frequent and for a longer duration. As a result of T-cell-mediated inflammation at...

Cite
Kazama S, Morimoto R, Kimura Y, et al. Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardiooncology. 2021;7(1):26doi: 10.1186/s40959-021-00112-z.
Kazama, S., Morimoto, R., Kimura, Y., Shibata, N., Ozaki, R., Araki, T., Mizutani, T., Oishi, H., Arao, Y., Kuwayama, T., Hiraiwa, H., Kondo, T., Furusawa, K., Shimokata, T., Okumura, T., Bando, Y. K., Ando, Y., & Murohara, T. (2021). Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardio-oncology (London, England), 7(1), 26. https://doi.org/10.1186/s40959-021-00112-z
Kazama, Shingo, et al. "Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review." Cardio-oncology (London, England) vol. 7,1 (2021): 26. doi: https://doi.org/10.1186/s40959-021-00112-z
Kazama S, Morimoto R, Kimura Y, Shibata N, Ozaki R, Araki T, Mizutani T, Oishi H, Arao Y, Kuwayama T, Hiraiwa H, Kondo T, Furusawa K, Shimokata T, Okumura T, Bando YK, Ando Y, Murohara T. Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardiooncology. 2021 Jul 06;7(1):26. doi: 10.1186/s40959-021-00112-z. PMID: 34229760; PMCID: PMC8259377.
Copy Download .nbib Format: NLM
The Sulfur Microbial Diet and Risk of Colorectal Cancer by Molecular Subtypes and Intratumoral Microbial Species in Adult Men.

Clinical and translational gastroenterology

Sikavi DR, Nguyen LH, Haruki K, Ugai T, Ma W, Wang DD, Thompson KN, Yan Y, Branck T, Wilkinson JE, Akimoto N, Zhong R, Lau MC, Mima K, Kosumi K, Morikawa T, Rimm EB, Garrett WS, Izard J, Cao Y, Song M, Huttenhower C, Ogino S, Chan AT.
PMID: 34333506
Clin Transl Gastroenterol. 2021 Aug 01;12(8):e00338. doi: 10.14309/ctg.0000000000000338.

INTRODUCTION: We recently described the sulfur microbial diet, a pattern of intake associated with increased gut sulfur-metabolizing bacteria and incidence of distal colorectal cancer (CRC). We assessed whether this risk differed by CRC molecular subtypes or presence of intratumoral...

Cite
Sikavi DR, Nguyen LH, Haruki K, et al. The Sulfur Microbial Diet and Risk of Colorectal Cancer by Molecular Subtypes and Intratumoral Microbial Species in Adult Men. Clin Transl Gastroenterol. 2021;12(8):e00338doi: 10.14309/ctg.0000000000000338.
Sikavi, D. R., Nguyen, L. H., Haruki, K., Ugai, T., Ma, W., Wang, D. D., Thompson, K. N., Yan, Y., Branck, T., Wilkinson, J. E., Akimoto, N., Zhong, R., Lau, M. C., Mima, K., Kosumi, K., Morikawa, T., Rimm, E. B., Garrett, W. S., Izard, J., Cao, Y., Song, M., Huttenhower, C., Ogino, S., & Chan, A. T. (2021). The Sulfur Microbial Diet and Risk of Colorectal Cancer by Molecular Subtypes and Intratumoral Microbial Species in Adult Men. Clinical and translational gastroenterology, 12(8), e00338. https://doi.org/10.14309/ctg.0000000000000338
Sikavi, Daniel R, et al. "The Sulfur Microbial Diet and Risk of Colorectal Cancer by Molecular Subtypes and Intratumoral Microbial Species in Adult Men." Clinical and translational gastroenterology vol. 12,8 (2021): e00338. doi: https://doi.org/10.14309/ctg.0000000000000338
Sikavi DR, Nguyen LH, Haruki K, Ugai T, Ma W, Wang DD, Thompson KN, Yan Y, Branck T, Wilkinson JE, Akimoto N, Zhong R, Lau MC, Mima K, Kosumi K, Morikawa T, Rimm EB, Garrett WS, Izard J, Cao Y, Song M, Huttenhower C, Ogino S, Chan AT. The Sulfur Microbial Diet and Risk of Colorectal Cancer by Molecular Subtypes and Intratumoral Microbial Species in Adult Men. Clin Transl Gastroenterol. 2021 Aug 01;12(8):e00338. doi: 10.14309/ctg.0000000000000338. PMID: 34333506; PMCID: PMC8323793.
Copy Download .nbib Format: NLM
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.

Investigational new drugs

Miura A, Sootome H, Fujita N, Suzuki T, Fukushima H, Mizuarai S, Masuko N, Ito K, Hashimoto A, Uto Y, Sugimoto T, Takahashi H, Mitsuya M, Hirai H.
PMID: 33409897
Invest New Drugs. 2021 Jun;39(3):724-735. doi: 10.1007/s10637-020-01019-9. Epub 2021 Jan 06.

Aurora kinase A, a mitotic kinase that is overexpressed in various cancers, is a promising cancer drug target. Here, we performed preclinical characterization of TAS-119, a novel, orally active, and highly selective inhibitor of Aurora A. TAS-119 showed strong...

Cite
Miura A, Sootome H, Fujita N, et al. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways. Invest New Drugs. 2021;39(3):724-735doi: 10.1007/s10637-020-01019-9.
Miura, A., Sootome, H., Fujita, N., Suzuki, T., Fukushima, H., Mizuarai, S., Masuko, N., Ito, K., Hashimoto, A., Uto, Y., Sugimoto, T., Takahashi, H., Mitsuya, M., & Hirai, H. (2021). TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways. Investigational new drugs, 39(3), 724-735. https://doi.org/10.1007/s10637-020-01019-9
Miura, Akihiro, et al. "TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways." Investigational new drugs vol. 39,3 (2021): 724-735. doi: https://doi.org/10.1007/s10637-020-01019-9
Miura A, Sootome H, Fujita N, Suzuki T, Fukushima H, Mizuarai S, Masuko N, Ito K, Hashimoto A, Uto Y, Sugimoto T, Takahashi H, Mitsuya M, Hirai H. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways. Invest New Drugs. 2021 Jun;39(3):724-735. doi: 10.1007/s10637-020-01019-9. Epub 2021 Jan 06. PMID: 33409897.
Copy Download .nbib Format: NLM
Feasible laparoscopic left trisectionectomy by Arantius' ligament approach (with video).

Surgical oncology

Haruki K, Onda S, Yasuda J, Ikegami T.
PMID: 34597864
Surg Oncol. 2021 Dec;39:101630. doi: 10.1016/j.suronc.2021.101630. Epub 2021 Jul 10.

BACKGROUND: Laparoscopic trisectionectomy is a technically challenging procedure with high rate of postoperative morbidity [1,2]. Arantius' ligament approach is useful to expose the root of middle hepatic vein, which is required in left trisectionectomy [3].METHODS: This video illustrates laparoscopic...

Cite
Haruki K, Onda S, Yasuda J, et al. Feasible laparoscopic left trisectionectomy by Arantius' ligament approach (with video). Surg Oncol. 2021;39:101630doi: 10.1016/j.suronc.2021.101630.
Haruki, K., Onda, S., Yasuda, J., & Ikegami, T. (2021). Feasible laparoscopic left trisectionectomy by Arantius' ligament approach (with video). Surgical oncology, 39101630. https://doi.org/10.1016/j.suronc.2021.101630
Haruki, Koichiro, et al. "Feasible laparoscopic left trisectionectomy by Arantius' ligament approach (with video)." Surgical oncology vol. 39 (2021): 101630. doi: https://doi.org/10.1016/j.suronc.2021.101630
Haruki K, Onda S, Yasuda J, Ikegami T. Feasible laparoscopic left trisectionectomy by Arantius' ligament approach (with video). Surg Oncol. 2021 Dec;39:101630. doi: 10.1016/j.suronc.2021.101630. Epub 2021 Jul 10. PMID: 34597864.
Copy Download .nbib Format: NLM
Urinary thioredoxin as a biomarker of renal redox dysregulation and a companion diagnostic to identify responders to redox-modulating therapeutics.

Antioxidants & redox signaling

Kasuno K, Yodoi J, Iwano M.
PMID: 34541903
Antioxid Redox Signal. 2021 Sep 20; doi: 10.1089/ars.2021.0194. Epub 2021 Sep 20.

SIGNIFICANCE: The development and progression of renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), are the result of heterogeneous pathophysiology that reflects a range of environmental factors and, in a lesser extent, genetic mutations. The...

Cite
Kasuno K, Yodoi J, Iwano M. Urinary thioredoxin as a biomarker of renal redox dysregulation and a companion diagnostic to identify responders to redox-modulating therapeutics. Antioxid Redox Signal. 2021;doi: 10.1089/ars.2021.0194.
Kasuno, K., Yodoi, J., & Iwano, M. (2021). Urinary thioredoxin as a biomarker of renal redox dysregulation and a companion diagnostic to identify responders to redox-modulating therapeutics. Antioxidants & redox signaling, . https://doi.org/10.1089/ars.2021.0194
Kasuno, Kenji, et al. "Urinary thioredoxin as a biomarker of renal redox dysregulation and a companion diagnostic to identify responders to redox-modulating therapeutics." Antioxidants & redox signaling vol. (2021). doi: https://doi.org/10.1089/ars.2021.0194
Kasuno K, Yodoi J, Iwano M. Urinary thioredoxin as a biomarker of renal redox dysregulation and a companion diagnostic to identify responders to redox-modulating therapeutics. Antioxid Redox Signal. 2021 Sep 20; doi: 10.1089/ars.2021.0194. Epub 2021 Sep 20. PMID: 34541903.
Copy Download .nbib Format: NLM
Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma.

Gland surgery

Yamazaki H, Iwasaki H, Suganuma N, Toda S, Masudo K, Nakayama H, Rino Y, Masuda M.
PMID: 33842230
Gland Surg. 2021 Mar;10(3):852-860. doi: 10.21037/gs-20-871.

BACKGROUND: Inflammatory biomarkers have been reported to be associated with anticancer drug efficacy in various cancers. This study aimed to investigate the associations between baseline inflammatory biomarkers or dynamics of neutrophil-to-lymphocyte ratio (NLR) and treatment outcomes of lenvatinib in...

Cite
Yamazaki H, Iwasaki H, Suganuma N, et al. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma. Gland Surg. 2021;10(3):852-860doi: 10.21037/gs-20-871.
Yamazaki, H., Iwasaki, H., Suganuma, N., Toda, S., Masudo, K., Nakayama, H., Rino, Y., & Masuda, M. (2021). Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma. Gland surgery, 10(3), 852-860. https://doi.org/10.21037/gs-20-871
Yamazaki, Haruhiko, et al. "Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma." Gland surgery vol. 10,3 (2021): 852-860. doi: https://doi.org/10.21037/gs-20-871
Yamazaki H, Iwasaki H, Suganuma N, Toda S, Masudo K, Nakayama H, Rino Y, Masuda M. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma. Gland Surg. 2021 Mar;10(3):852-860. doi: 10.21037/gs-20-871. PMID: 33842230; PMCID: PMC8033089.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 244 entries